Der „weltweit erste“ von KI entwickelte Impfstoff zeigt in frühen Tests am Menschen eine Immunreaktion
https://interestingengineering.com/ai-robotics/cambridge-ai-designed-universal-vaccine-phase-1-trial
Der „weltweit erste“ von KI entwickelte Impfstoff zeigt in frühen Tests am Menschen eine Immunreaktion
https://interestingengineering.com/ai-robotics/cambridge-ai-designed-universal-vaccine-phase-1-trial
2 Kommentare
A Cambridge-led team has developed an early-stage vaccine platform that uses computational design to generate broad immune protection against entire virus families, with the aim of reducing the need to repeatedly update vaccines as viruses mutate.
The approach, developed by researchers at the University of Cambridge and spin-out DIOSynVax (DVX) Ltd, has now reached a key milestone after its first human clinical trial showed safety and immune response in volunteers. The trial focused on a universal Sarbeco coronavirus vaccine designed to target a wide range of related viruses, including SARS-CoV-2 and SARS.
the design cycle collapsing from years to months is what actually matters here. once you can simulate immune response in silico, the bottleneck shifts from lab time to regulatory bandwidth. i think we’ll see the first fully AI-designed drug approved before 2028. the real speedup is paperwork. the trials are already half-modeled before the first patient signs.